The US Food and Drug Administration (FDA) has approved three generations of small molecule tyrosine kinase inhibitors (TKIs) Gefitinib/Erlotinib/Afatinib/Osimertinib as a first line treatment for lung cancer patients harboring EGFR mutations6. This evidence concerns the gene EGFR and lung carcinoma.